

# University of Wollongong - Research Online

## Thesis Collection

Title: Neurotransmitter receptor binding in the posterior cingulate cortex in schizophrenia and in the phencyclidine mouse model: an exploration of the NMDA hypofunction hypothesis of schizophrenia

Author: Kelly Newell

Year: 2007

Repository DOI:

### Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

**Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.**

Research Online is the open access repository for the University of Wollongong. For further information contact the UOW Library: [research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

2007

## Neurotransmitter receptor binding in the posterior cingulate cortex in schizophrenia and in the phencyclidine mouse model: an exploration of the NMDA hypofunction hypothesis of schizophrenia

Kelly Newell

*University of Wollongong*, [knewell@uow.edu.au](mailto:knewell@uow.edu.au)

Follow this and additional works at: <https://ro.uow.edu.au/theses>

### University of Wollongong

#### Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

### Recommended Citation

Newell, Kelly, Neurotransmitter receptor binding in the posterior cingulate cortex in schizophrenia and in the phencyclidine mouse model: an exploration of the NMDA hypofunction hypothesis of schizophrenia, PhD thesis, School of Health Sciences, University of Wollongong, 2007. <http://ro.uow.edu.au/theses/610>

## **NOTE**

This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

## **UNIVERSITY OF WOLLONGONG**

### **COPYRIGHT WARNING**

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

**NEUROTRANSMITTER RECEPTOR  
BINDING IN THE POSTERIOR CINGULATE  
CORTEX IN SCHIZOPHRENIA AND IN THE  
PHENCYCLIDINE MOUSE MODEL**

**AN EXPLORATION OF THE NMDA  
HYPOFUNCTION HYPOTHESIS OF  
SCHIZOPHRENIA**

A thesis submitted in fulfillment of the  
requirements for the award of the degree

DOCTOR OF PHILOSOPHY

From

SCHOOL OF HEALTH SCIENCES  
UNIVERSITY OF WOLLONGONG

By

Kelly Newell

2007

## **CERTIFICATION**

I, Kelly Newell, declare that this thesis, submitted in fulfillment of the requirements for the award of Doctor of Philosophy, in the School of Health Sciences, University of Wollongong, is entirely my own work unless otherwise referenced or acknowledged. This manuscript has not been submitted for qualifications at any other academic institution.

Kelly Newell

May 2007

## ACKNOWLEDGEMENTS

I would like to sincerely thank several people, without whose assistance and guidance this research project and thesis would not have been possible.

To my supervisors Professor Xu-Feng Huang and Dr Katerina Zavitsanou, I would like to thank you for your encouragement, guidance and support. In particular, thanks to Xu-Feng for your support in the preparation of my published papers and my thesis, and for your continuous support throughout this period of study. Your motivational support and encouragement was greatly appreciated, and this thesis would not have been possible without it. I thank you for your commitment to help see this project through to its final completion, and your wise guidance during its development. Finally, I thank you for providing me with the opportunity to work with a talented team of researchers.

This work was supported by the St. George Foundation, and the Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD) utilizing infrastructure funding from NSW Health. I am sincerely grateful to NISAD and the St George Foundation for giving me the financial ability to conduct this research. I am very proud to be a part of NISAD.

Thank you to Ms Mei Han for your help sacrificing the mice in the animal studies.

To Associate Professor Ken Russel and Professor David Griffiths, School of Mathematics and Applied Statistics, University of Wollongong, for suggestions regarding the statistical analyses.

Post-mortem brain tissue was obtained from the Tissue Resource Center, which is supported by the University of Sydney, NISAD, National Institute of Alcohol Abuse and Alcoholism and NSW Department of Health. Thank you for providing the brain tissue and clinical and demographic information regarding the schizophrenia and control post-mortem brain tissue.

To my family and friends for your continual support and understanding throughout this period of study. Special thanks to my sister Karen, and fellow student Teresa for enthusiastically reading my final thesis and providing editorial advice.

Finally, special thanks to my husband Stephen, who provided tremendous support throughout my PhD and for his continual faith in me over the duration of this study.

## **PUBLICATIONS**

The following publications and presentations have arisen directly from the work conducted for this thesis.

### **Publications in Refereed Journals**

**Newell, K.A.**, Zavitsanou, K., and Huang, X.F. Short and long-term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. *Journal of Neural Transmission*, In Press.

**Newell, K.A.**, Zavitsanou, K., and Huang, X.F. Opposing short and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. *Journal of Neuroscience Research*, 85: 1358-1363, 2007.

**Newell, K.A.**, Zavitsanou, K., Kum-Jew, S. and Huang, X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. *Progress in Neuropsychopharmacology & Biological Psychiatry*, 31: 225-233, 2007.

**Newell, K.A.**, Deng, C., and Huang, X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. *Experimental Brain Research*, 172 (4): 556-560, 2006.



**Newell, K.A.,** Zavitsanou, K., and Huang, X.F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. *NeuroReport*, 16(12): 1363-1367, 2005.

## **Publications in Conference Proceedings**

**Newell, K.A.** Zavitsanou, and Huang X.F. The posterior cingulate cortex: a site of altered neural circuitry in schizophrenia and in NMDA hypofunction. *Schizophrenia Bulletin*, 33(2): 321, 2007.

**Newell, K.A.,** Zavitsanou, K., and Huang, X.F. NMDA and muscarinic M1/4 receptor binding density is decreased 2 weeks after, but not immediately after chronic PCP treatment. *Proceedings of the Australian Neuroscience Society, the 26<sup>th</sup> Annual Meeting*. 17: 105, Sydney 2006.

**Newell, K.A.,** and Huang, X.F. Increased NMDA receptor density in the posterior cingulate cortex in schizophrenia. *Proceedings of the Australian Neuroscience Society, the 25<sup>th</sup> Annual Meeting*. 16:124, Perth 2005.

**Newell, K.A.,** Zavitsanou, K., and Huang, X.F. Alterations in the serotonin and cannabinoid systems in the posterior cingulate cortex in schizophrenia. *Proceedings of the Australian Neuroscience Society, the 24<sup>th</sup> Annual Meeting*. 15:138, Melbourne 2004.

**Newell, K.A.**, Klose, B., Zavitsanou, K., Han, M., and Huang, X.F. Effects of clozapine and haloperidol on motor activity in the chronic PCP mouse model. 7<sup>th</sup> Biennial Australasian Schizophrenia Conference. 7:115, Sydney, 2002.

### **Additional Publications**

The following publications have arisen from other projects I have been involved in throughout my doctoral studies.

Han, M., **Newell, K.A.**, Zavitsanou, K., Deng, C., and Huang, X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. Journal of Neuroscience Research. Submitted.

Han, M., Deng, C., Burne, T.H.J., **Newell, K.A.**, and Huang, X.F. Olanzapine-induced weight gain is related to a reduction in histamine H1 receptor mRNA expression in the rat hypothalamus. Schizophrenia Research. Submitted.

Deng, C., Han, M., **Newell, K.A.**, and Huang, X.F. No changes in cannabinoid CB1 receptor binding density in the superior temporal gyrus in schizophrenia. Schizophrenia Bulletin, 33(2): 308, 2007.

Han, M., Deng, C., **Newell, K.A.**, and Huang, X.F. Histamine mRNA expression is decreased in the rat hypothalamus following olanzapine treatment. Schizophrenia Bulletin, 33(2): 317, 2007.

Huang, X.F., du Bois, T., Hsu, C., Eftimovska, J., Tan, Y.Y., Zavitsanou, K., **Newell, K.A.**, and Deng, C. NMDA receptor hypofunction during early brain development: relevance to schizophrenia. *Schizophrenia Bulletin*, 33(2): 317, 2007.

Zavitsanou, K., Nguyen, V., **Newell, K.**, Ballantyne, P., and Huang, X.F. Increased [<sup>3</sup>H]MK801 binding in the cingulate cortex of the rat after a single injection of phencyclidine. *Proceedings of the Australian Neuroscience Society, the 26<sup>th</sup> Annual Meeting*. 17: 102, Sydney, 2006.

Han, M. Zavitsanou, K. **Newell, K.**, and Huang, X.F. Increased CB1 mRNA in the cortical areas of mice prone to diet-induced obesity. *Proceedings of the Australian Neuroscience Society, the 24<sup>th</sup> Annual Meeting*. 15:113, Melbourne 2004.

Huang, X.F., Han, M., **Newell, K.**, and Zavitsanou, K. A low level of Y1 and Y5 gene expression may contribute to the prevention of chronic high energy diet-induced obesity. *Proceedings of the Australian Neuroscience Society, the 23<sup>rd</sup> Annual Meeting*. 14:228, Adelaide 2003.

## Abstract

Schizophrenia is a severe psychiatric disorder with no clear cause. Recent evidence suggests that N-methyl-D-aspartate (NMDA) receptor hypofunction may underlie the pathogenesis of schizophrenia. The posterior cingulate cortex (PCC) has been shown to be the most susceptible brain region to damage caused by NMDA hypofunction in rodents. This suggests that the PCC may play an important role in schizophrenia pathology. However, studies examining neurotransmitter balance in the PCC in schizophrenia have until now been neglected. Furthermore, the long-term consequences of NMDA hypofunction on neurotransmitter balance in animal models have not been studied. The aims of this study were to investigate neurotransmitter receptor binding profiles in the PCC in schizophrenia, while also examining the effects of chronic phencyclidine (PCP; an NMDA antagonist) treatment on neurotransmitter receptor binding in mouse brain in the long-term following treatment. To achieve these aims, the study was divided into two parts.

In experimental part A, PCC sections from 10 schizophrenia and 11 control subjects matched for age, gender and post-mortem interval were obtained from the Tissue Resource Center, Sydney. Using quantitative autoradiography, the density of several neurotransmitter receptors was examined. The results demonstrated specific alterations in neurotransmitter receptors in the PCC in schizophrenia. Specifically, increased NMDA, gamma-aminobutyric acid A (GABA<sub>A</sub>) and cannabinoid 1 (CB1) receptor density was found in this region, along with reduced muscarinic 1/4 (M1/4) and serotonin 2A (5-hydroxy-tryptamine, 5HT<sub>2A</sub>) receptor density. No changes were found in  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate or M2/4 receptor density in the PCC in schizophrenia subjects compared to controls. These

results have shown for the first time that there are specific neurotransmitter imbalances in this region, and it is possible that these changes stem from NMDA hypofunction.

In experimental part B, mice were treated chronically (14 days) with PCP. Using quantitative autoradiography the density of several receptors was examined in the short (1hr and 24hr) and long-term (14 days) following chronic PCP treatment. In addition, clozapine and haloperidol were tested for their ability to prevent the PCP-induced alterations in neurotransmitter receptor density. The results showed opposing effects of PCP treatment on neurotransmitter receptor density in the short compared to the long-term. While there were limited increases in NMDA receptor density in the short-term, there were widespread reductions in NMDA receptor density in the long-term following chronic PCP treatment. Muscarinic M1/4 receptor binding, which was increased in the short-term, showed reductions in the long-term in the limbic system, caudate-putamen and cortex, but not in the thalamus in which no change was found. Clozapine and haloperidol treatments were both unable to prevent the PCP-induced long-term changes in receptor density.

In conclusion, this study has provided new information regarding neurotransmitter alterations in the PCC in schizophrenia and in mouse brain in the long-term following chronic PCP treatment. These findings may assist not only in understanding the pathology of schizophrenia, but also for designing new pharmacological treatments for this disease.

# Table of Contents

	<b>Page</b>
CERTIFICATION .....	2
ACKNOWLEDGEMENTS .....	3
PUBLICATIONS .....	5
ABSTRACT .....	9
TABLE OF CONTENTS .....	11
LIST OF FIGURES .....	16
LIST OF TABLES .....	18
LIST OF ABBREVIATIONS .....	20
 <b>CHAPTER 1: SCHIZOPHRENIA - A REVIEW .....</b>	 <b>21</b>
1.1 What is Schizophrenia? .....	21
1.2 What is the Cause of Schizophrenia? .....	21
1.3 Schizophrenia Hypotheses .....	22
1.4 NMDA hypofunction hypothesis of schizophrenia .....	23
1.5 Rodent NMDA receptor hypofunction model .....	27
1.6 Why Research Schizophrenia? .....	30
 <b>CHAPTER 2: REVIEW OF THE LITERATURE.....</b>	 <b>32</b>
2.1 General Introduction .....	32
2.2 The Posterior Cingulate Cortex.....	33
2.2.1 Relevance to Schizophrenia .....	34
2.3 Glutamate .....	36
2.3.1 Schizophrenia.....	38
2.3.2 NMDA receptor hypofunction .....	40
2.4 GABA .....	42
2.4.1 Schizophrenia.....	43
2.4.2 NMDA receptor hypofunction .....	45
2.5 Acetylcholine .....	47
2.5.1 Schizophrenia.....	49
2.5.2 NMDA receptor hypofunction .....	50
2.6 Serotonin .....	51
2.6.1 Schizophrenia.....	52
2.6.2 NMDA receptor hypofunction .....	56
2.7 Cannabinoid .....	57
2.7.1 Schizophrenia.....	59
2.7.2 NMDA receptor hypofunction .....	60
2.8 Summary .....	61
2.9 Aims of the Study .....	62
2.10 Significance of the study .....	62
2.11 Hypotheses .....	63

**EXPERIMENTAL PART A: EXAMINATION OF THE  
NEUROTRANSMITTER RECEPTOR BINDING PROFILES IN THE  
POSTERIOR CINGULATE CORTEX IN SCHIZOPHRENIA ..... 64**

**CHAPTER 3: DIFFERENTIAL ALTERATIONS IN IONOTROPIC  
GLUTAMATE RECEPTOR BINDING IN THE POSTERIOR CINGULATE  
CORTEX IN SCHIZOPHRENIA. .... 65**

3.1 Introduction .....	65
3.2 Materials and methods .....	66
3.2.1 Post-mortem brain tissue.....	66
3.2.2 Autoradiography .....	68
3.2.3 Quantitative analysis of autoradiograms.....	69
3.2.4 Statistical analysis .....	70
3.3 Results.....	70
3.3.1 Laminar distribution of [ <sup>3</sup> H]MK-801, [ <sup>3</sup> H]AMPA and [ <sup>3</sup> H]kainate binding in the PCC .....	70
3.3.2 Schizophrenia related effects on [ <sup>3</sup> H]MK-801, [ <sup>3</sup> H]AMPA, and [ <sup>3</sup> H]kainate binding in the PCC .....	72
3.3.3 Possible effects of continuous and non-continuous confounding variables.....	74
3.4 Discussion .....	74
3.4.1 Ionotropic glutamate receptor binding in the PCC in schizophrenia.....	75
3.4.2 Possible effects of medication and suicide on the receptor binding in the PCC.....	77
3.5 Conclusion .....	77

**CHAPTER 4: ALTERATIONS OF MUSCARINIC AND GABA RECEPTOR  
BINDING IN THE POSTERIOR CINGULATE CORTEX IN  
SCHIZOPHRENIA..... 79**

4.1 Introduction .....	79
4.2 Materials and methods .....	80
4.2.1 Post-mortem brain tissue.....	80
4.2.2 Autoradiography .....	80
4.2.3 Quantitative and statistical analyses of autoradiograms .....	81
4.3 Results.....	82
4.3.1 Laminar distribution of [ <sup>3</sup> H]pirenzepine, [ <sup>3</sup> H]AF-DX 384 and [ <sup>3</sup> H]muscimol binding in the PCC .....	82
4.3.2 Schizophrenia related effects on [ <sup>3</sup> H]pirenzepine, [ <sup>3</sup> H]AF-DX 384 and [ <sup>3</sup> H]muscimol binding in the PCC .....	83
4.3.3 Possible effects of continuous and non-continuous confounding variables.....	86
4.4 Discussion .....	86
4.4.1 M1/4, M2/4 and GABA <sub>A</sub> receptor binding in the PCC in schizophrenia .....	87
4.4.2 Possible effects of medication and suicide on the receptor binding in the PCC.....	90
4.5 Conclusion .....	92

**CHAPTER 5: ALTERATIONS IN SEROTONIN AND CANNABINOID  
RECEPTOR BINDING IN THE POSTERIOR CINGULATE CORTEX IN  
SCHIZOPHRENIA..... 93**

5.1 Introduction .....	93
5.2 Materials and Methods.....	94
5.2.1 Post-mortem human brain tissue.....	94
5.2.2 Autoradiography .....	94

5.2.4 Quantitative Analysis of Autoradiograms.....	95
5.2.5 Statistical Analysis.....	95
5.3 Results.....	96
5.3.1 Laminar distribution of [ <sup>3</sup> H]spiperone, [ <sup>3</sup> H]SR141716A and [ <sup>3</sup> H]CP-55940 binding in the PCC.....	96
5.3.2 Schizophrenia related effects on [ <sup>3</sup> H]spiperone, [ <sup>3</sup> H]SR141716A and [ <sup>3</sup> H]CP-55940 binding in the PCC.....	98
5.3.3 Possible effects of confounding variables.....	99
5.4 Discussion.....	100
5.4.1 5HT <sub>2A</sub> receptor binding in the PCC in schizophrenia.....	101
5.4.2 CB1 receptor binding in the PCC in schizophrenia.....	104
5.5 Conclusion.....	107

## **EXPERIMENTAL PART B: CONSEQUENCES OF NMDA RECEPTOR HYPOFUNCTION ON NEUROTRANSMITTER BALANCE IN A MOUSE MODEL..... 109**

<b>CHAPTER 6: VERIFYING THE EFFECTS OF PHENCYCLIDINE, CLOZAPINE AND HALOPERIDOL ON LOCOMOTOR ACTIVITY IN MICE.....</b>	<b>110</b>
6.1 Introduction.....	110
6.2 Materials and Methods.....	111
6.2.1 Animals.....	111
6.2.2 Drug Treatment.....	112
6.2.3 Locomotor testing.....	112
6.2.4 Statistical Analysis.....	113
6.3 Results.....	114
6.3.1 The effects of chronic PCP, clozapine, and haloperidol treatment on locomotor activity measured in the post-injection phase.....	114
6.3.2 The effects of chronic PCP, clozapine, and haloperidol treatment on locomotor activity measured in the pre-injection phase.....	116
6.4 Discussion.....	118
6.4.2 Locomotor activity during the post-injection phase.....	119
6.4.3 Locomotor activity during the pre-injection phase.....	120
6.5 Conclusion.....	121

<b>CHAPTER 7: DIFFERENTIAL SHORT AND LONG TERM CHANGES IN NMDA RECEPTOR BINDING IN MOUSE BRAIN FOLLOWING CHRONIC PHENCYCLIDINE TREATMENT.....</b>	<b>123</b>
7.1 Introduction.....	123
7.2 Materials and Methods.....	124
7.2.1 Animals and Drug Treatment.....	124
7.2.4 Receptor autoradiography.....	125
7.2.5 Quantification and statistical analysis.....	126
7.3 Results.....	126
7.3.2 The short-term effects on [ <sup>3</sup> H]MK-801 binding following chronic PCP treatment.....	127
7.3.3 The long-term effects on [ <sup>3</sup> H]MK-801 binding following chronic PCP treatment.....	129
7.4 Discussion.....	130
7.4.1 Distribution of NMDA receptor binding in control animals.....	130



7.4.2 Short-term effects on NMDA receptor binding following chronic PCP treatment.....	131
7.4.3 Long-term effects on NMDA receptor binding following chronic PCP treatment.....	133
7.5 Conclusion .....	135

## **CHAPTER 8: OPPOSING SHORT AND LONG-TERM EFFECTS ON M1/4 MUSCARINIC RECEPTOR BINDING IN MOUSE BRAIN FOLLOWING CHRONIC PHENCYCLIDINE TREATMENT..... 137**

8.1 Introduction .....	137
8.2 Materials and Methods .....	138
8.2.1 Animals and Drug treatment .....	138
8.2.2 Receptor autoradiography, quantification and statistical analysis .....	138
8.3 Results .....	138
8.3.1 The short-term effects on [ <sup>3</sup> H]pirenzepine binding following chronic PCP treatment.....	139
8.3.3 The long-term effects on [ <sup>3</sup> H]pirenzepine binding following chronic PCP treatment.....	140
8.4 Discussion .....	141
8.4.1 Distribution of M1/4 receptor binding in control animals .....	142
8.4.2 M1/4 receptor binding in the short-term following chronic PCP treatment ..	142
8.4.3 M1/4 receptor binding in the long-term following chronic PCP treatment ...	143
8.5 Conclusion .....	145

## **CHAPTER 9: CAN THE PHENCYCLIDINE-INDUCED NEUROTRANSMITTER ALTERATIONS BE REVERSED OR PREVENTED BY ANTIPSYCHOTIC DRUG TREATMENT? ..... 146**

9.1 Introduction .....	146
9.2 Materials and Methods .....	147
9.2.1 Animals and Drug Treatment.....	147
9.2.2 Receptor autoradiography, quantification and statistical analysis .....	148
9.3 Results .....	149
9.3.1 The effects of 14-day clozapine and haloperidol treatment on [ <sup>3</sup> H]MK-801 binding .....	149
9.3.2 The effects of 14-day clozapine and haloperidol treatment on [ <sup>3</sup> H]pirenzepine binding .....	152
9.3.3 [ <sup>3</sup> H]MK-801 binding in the brains of mice treated for 14 days with PCP followed by 1 day of antipsychotic drug treatment.....	154
9.3.4 [ <sup>3</sup> H]Pirenzepine binding in the brains of mice treated for 14 days with PCP followed by 1 day of antipsychotic drug treatment.....	155
9.3.5 [ <sup>3</sup> H]MK-801 binding in the brains of mice treated for 14 days with PCP followed by 14 days of antipsychotic drug treatment .....	158
9.3.6 [ <sup>3</sup> H]Pirenzepine binding in the brains of mice treated for 14 days with PCP followed by 14 days of antipsychotic drug treatment .....	160
9.4 Discussion .....	162
9.4.1 The effects of chronic antipsychotic drug treatment on NMDA receptor binding in mouse brain.....	162
9.4.2 The effects of chronic antipsychotic drug treatment on M1/4 receptor binding in mouse brain .....	166

9.4.3 The effects of acute and chronic antipsychotic drug treatment on NMDA receptor binding in PCP-treated mouse brain .....	168
9.4.4 The effects of acute and chronic antipsychotic drug treatment on M1/4 receptor binding in PCP-treated mouse brain .....	169
9.5 Conclusion .....	171
<b>CHAPTER 10: CONCLUSIONS AND RECOMMENDATIONS.....</b>	<b>172</b>
10.1 Overall Conclusion .....	172
10.2 Recommendations for Further Research.....	174
<b>REFERENCES.....</b>	<b>176</b>

## List of Figures

Figure	Page
1.1 Schematic of the NMDA receptor.....	24
1.2 Model of NMDA hypofunction in the PCC and its associated psychosis circuit.....	30
2.1 The cingulate gyrus showing anterior and posterior divisions.....	33
3.1 Digital autoradiograms obtained with the Beta-Imager showing [ <sup>3</sup> H]MK-801, [ <sup>3</sup> H]AMPA, and [ <sup>3</sup> H]kainate binding in the posterior cingulate cortex of one schizophrenia and one control case.....	72
3.2 Scatterplots of [ <sup>3</sup> H]MK-801 (A), [ <sup>3</sup> H]AMPA (B), and [ <sup>3</sup> H]kainate (C) receptor binding in the posterior cingulate cortex of control and schizophrenia cases....	73
4.1 Digital autoradiograms obtained with the Beta-Imager showing [ <sup>3</sup> H]pirenzepine [ <sup>3</sup> H]AF-DX 384 binding, and [ <sup>3</sup> H]muscimol binding in the posterior cingulate cortex of one control and one schizophrenia case.....	83
4.2 (A) Histogram of [ <sup>3</sup> H]pirenzepine binding in layers I-II and III-VI of the posterior cingulate cortex of schizophrenia (non-suicides) and control groups. (B) Histogram of [ <sup>3</sup> H]muscimol binding in layers I-IV and V-VI of the posterior cingulate cortex of schizophrenia and control groups.....	85
4.3 Scatterplot showing significant correlations between GABA <sub>A</sub> receptor binding (layers I-IV) and M1/4 receptor binding (layers III-VI) in the posterior cingulate cortex.....	85
5.1 Digital autoradiograms obtained with the Beta-Imager showing [ <sup>3</sup> H]spiperone, [ <sup>3</sup> H]SR141716A binding, and [ <sup>3</sup> H]CP-55940 binding in the posterior cingulate cortex of one control and one schizophrenia case.....	97
5.2 Histogram of [ <sup>3</sup> H]spiperone binding in layers II-V of the posterior cingulate cortex of schizophrenia and control groups.....	98
5.3 (A) Histogram of [ <sup>3</sup> H]SR141716A binding across all layers of the posterior cingulate cortex of schizophrenia and control groups. (B) Histogram of [ <sup>3</sup> H]CP-55940 binding in layers I-II of the posterior cingulate cortex of schizophrenia and control groups.....	99
6.1 Diagram of the locomotor box.....	113
6.2 Locomotor activity of saline and PCP treated mice, as measured in the post-injection phase on days 1, 2, 8, and 14.....	115
6.3 Locomotor activity of saline, clozapine, and haloperidol treated mice, measured in the post-injection phase on days 1, 2, 8, and 14.....	115

<b>6.4</b>	Locomotor activity of saline and PCP treated mice, measured in the pre-injection phase on days 2, 8, and 14.....	117
<b>6.5</b>	Locomotor activity of saline, clozapine, and haloperidol treated mice, measured in the pre-injection phase on days 2, 8, and 14.....	117
<b>7.1</b>	Representative autoradiographs of coronal mouse brain sections which illustrate total and non-specific [ <sup>3</sup> H]MK-801 binding.....	127
<b>7.2</b>	The Short-term effects on [ <sup>3</sup> H]MK801 binding in mouse brain following chronic PCP treatment.....	128
<b>7.3</b>	The long-term effects on [ <sup>3</sup> H]MK801 binding in mouse brain following chronic PCP treatment.....	130
<b>8.1</b>	Representative autoradiographs of coronal mouse brain sections which illustrate total and non-specific [ <sup>3</sup> H]pirenzepine binding.....	139
<b>8.2</b>	The short-term effects on [ <sup>3</sup> H]pirenzepine binding in mouse brain following chronic days of PCP treatment.....	140
<b>8.3</b>	The long-term effects on [ <sup>3</sup> H]pirenzepine binding in mouse brain following chronic days of PCP treatment.....	141

## List of Tables

Table	Page
<b>Table 1.1</b>	Parallels between the behavioural effects of PCP in rodents and schizophrenia symptoms.....28
<b>Table 2.1</b>	A comparison of the anterior cingulate cortex and posterior cingulate cortex.....34
<b>Table 2.2</b>	The effects of antipsychotic drug treatment on glutamate receptor binding in rodent brain.....39
<b>Table 2.3</b>	The effects of NMDA antagonist treatment on glutamate receptor binding in rodent brain.....41
<b>Table 2.4</b>	The effects antipsychotic drug treatment on the GABAergic system in rodent brain.....45
<b>Table 2.5</b>	Summary of 5-HT <sub>2</sub> receptor binding in schizophrenia.....54
<b>Table 2.6</b>	The effects of antipsychotic drug treatment on the serotonin system in rodent brain.....56
<b>Table 3.1</b>	Demographic data, characteristics and medication status of schizophrenia subjects and controls.....67
<b>Table 3.2</b>	Schizophrenia and control subjects used for [ <sup>3</sup> H]MK-801, [ <sup>3</sup> H]AMPA, and [ <sup>3</sup> H]kainate receptor binding.....68
<b>Table 4.1</b>	Schizophrenia and control subjects used for [ <sup>3</sup> H]pirenzepine, [ <sup>3</sup> H]AF-DX 384, and [ <sup>3</sup> H]muscimol receptor binding.....80
<b>Table 5.1</b>	Schizophrenia and control subjects used for [ <sup>3</sup> H]spiperone, [ <sup>3</sup> H]SR141716A, and [ <sup>3</sup> H]CP55940 receptor binding.....94
<b>Table 9.1</b>	[ <sup>3</sup> H]MK-801 binding densities in brains of mice treated with saline, clozapine or haloperidol for 14 days.....151
<b>Table 9.2</b>	[ <sup>3</sup> H]Pirenzepine binding densities in brains of mice treated with saline, clozapine or haloperidol for 14 days.....153
<b>Table 9.3</b>	[ <sup>3</sup> H]MK-801 binding densities in brains of mice treated with saline, PCP, clozapine and/or haloperidol for 14 days.....155
<b>Table 9.4</b>	[ <sup>3</sup> H]Pirenzepine binding densities in brains of mice treated with saline, PCP, clozapine and/or haloperidol for 14 days.....157
<b>Table 9.5</b>	[ <sup>3</sup> H]MK-801 binding densities in the brains of mice treated for 28 days with saline, PCP, clozapine, and/or haloperidol.....159

<b>Table 9.6</b>	[ <sup>3</sup> H]Pirenzepine binding densities in the brains of mice treated for 28 days with saline, PCP, clozapine, and/or haloperidol.....	161
------------------	---	-----

## List of Abbreviations

Abbreviations used throughout this thesis are defined below.

Abbreviations	Definition
5-HT	5-hydroxy-tryptamine
Acb	Nucleus accumbens
ACC	Anterior cingulate cortex
AMPA	$\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
APD	Antipsychotic drug
BSA	Bovine serum albumin
CNS	Central nervous system
CPu	Caudate-putamen
D-AP5	D-2-amino-5-phosphopentanoate
DSM	Diagnostic and Statistical Manual of Mental Disorders
EDTA	Ethylenediamine tetraacetic acid
GABA	Gamma-aminobutyric acid
GAD	Glutamic acid decarboxylase
GAT 1	GABA transporter 1
HEPES	N-(2-Hydroxyethyl) piperazine-N'-2-ethane sulfonic acid
LSD	Lysergic acid diethylamide
LV	Lateroventral
MRI	Magnetic resonance imaging
NHMRC	National Health and Medical Research Council
NMDA	N-methyl-D-aspartate
PCC	Posterior cingulate cortex
PCP	Phencyclidine
PET	Positron emission tomography
RSC	Retrosplenial cortex
$\Delta^9$ -THC	$\Delta^9$ -tetrahydrocannabinol